Prevalence and prognostic significance of sMUC-1 levels in plasma cell dyscrasias

British Journal of Haematology

Volumn 121, Issue 5, 2003, Pages 772-774

  Luminari, Stefano ^a   Goldaniga, Maria ^b   Ceccherelli, Fulvia ^b   Guffanti, Andrea ^c   Bombardieri, Emilio ^d   Marcheselli, Raffaella ^a   Cro, Lilla ^b   Colombi, Mariangela ^b   Federico, Massimo ^a   Baldini, Luca ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c FATEBENEFRATELLI HOSPITAL   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

CA15.3; Multiple myeloma; Overall survival; Prognostic factors; sMUC 1

Indexed keywords

MUCIN 1;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PLASMA CELL DYSCRASIA; PLASMA CELL LEUKEMIA; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION;

ADULT; AGED; AGED, 80 AND OVER; CA-15-3 ANTIGEN; HUMANS; MIDDLE AGED; PARAPROTEINEMIAS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0037832583     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04353.x     Document Type: Article

References (9)

1. Colomer, R., Ruibal, A., Genolla, J. & Salvador, L. (1989) Circulating CA 15-3 antigen levels in non-mammary malignancies. British Journal of Cancer, 59, 283-286.
2. Hayes, D.F., Sekine, H., Ohno, T., Abe, M., Keefe, K. & Kufe, D. (1985) Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. Journal of Clinical Investigations, 75, 1671-1678.
3. MacLean, G.D., Reddish, M.A. & Longenecker, B.M. (1997) Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients. Journal of Immunotherapy. 20, 70-78.
4. Patton, S., Gendler, S.J. & Spicer, A.P. (1995) The epithelial mucin, MUC-1, of milk, mammary gland and other tissues. Biochemica Biophysics Acta, 1241, 407-423.
5. Price, M.R., Clarke, A.J., Robertson, J.F., O'Sullivan, C., Baldwin, R.W. & Blamey, R.W. (1990) Detection of polymorphic epithelial mucins in the serum of systemic breast cancer patients using the monoclonal antibody, NCRC-11. Cancer Immunology and Immunotherapy, 31, 269-272.
6. Richards, E.R., Devine, P.L., Quin, R.J., Fontenot, J.D., Ward, B.G. & McGuckin, M.A. (1998) Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunology and Immunotherapy, 46, 245-252.
7. Treon, S.P., Mollick, J.A., Urashima, M., Teoh, G., Chauhan, D., Ogata, A., Raje, N., Hilgers, J.H., Nadler, L., Belch, A.R., Pilarski, L.M. & Anderson, K. (1999) Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood, 93, 1287-1298.
8. Treon, S.P., Maimonis, P., Bua, D., Young, G., Raje, N., Mollick, J., Chauhan, D., Tai, Y.T., Hideshima, T., Shima, Y., Hilgers, J., von Mensdorff-Pouilly, S., Belch, A.R., Pilarski, L.M. & Anderson, K. (2000) Elevated soluble MUC-1 levels and decreased anti-MUC-1 antibody levels in patients with multiple myeloma. Blood, 96, 3147-3153.
9. Vizcarra, E., Lluch, A., Cibrian, R., Jarque, F., Alberola, V., Belloch, V. & Garcia-Conde, J. (1996) Value of CA 15.3 in breast cancer and comparison with CEA and TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis. Breast Cancer Research Treatment, 37, 209-216.